|Bid||1.9800 x 800|
|Ask||6.7400 x 900|
|Day's Range||4.8400 - 5.2060|
|52 Week Range||4.1500 - 14.9000|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.50|
Subscribe to Yahoo Finance Plus to view Fair Value for XGN
Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022. Ron Rocca, president and chief Executive officer; Kamal Adawi, chief financial officer; Mark Hazeltine, chief operating officer, will host this afternoon's call. Before we get started, I'd like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic test for rheumatoid arthritis using the AVISE® RADR platform. The goal of the Treatment stratIfication using Gene Expression profiling in Rheumatoid arthritis (TiGER) study is to assess whether certain biomarkers from synovial biopsies of inflame